Skip to Content
Søk Menu

Belantamab mafodotin kan endre behandlingen av myelomatose og gi pasientene lengre overlevelse

/ Tobias S. Slørdahl / Jan Andreasen
Hematologisk Høstmøte 25Myelomatose

Verna: Norwegian dermatologists» experience in treating moderate-to-severe plaque psoriasis with brodalumab in relation to clinical trials

/ LEO Pharma / Tore Morken / Evelina Buinauskaite / Ernst Veer / Thrasyvoulos Tzellos

AML Insights – November Update: What’s New in the Field

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

Nordic AML Insights – November Update

/ Amanda Feldballe Bernholm / Jan Andreasen
AML

HER2-negative Breast Cancer – A Pathologist’s Perspective

/ Gilead
Brystkreft

Danish Study: Tattoo Ink May Increase Risk of Lymphoma and Skin Cancer

/ Signe Bedsted Clemmensen / Jan Andreasen
HudcancerLymfom

Towards Personalized MS Therapy: microRNAs as Early Indicators of Cladribine Response

/ Jan Andreasen
MS

Immunotherapy Has Sparked Hope That Cancer Could One Day Be Cured

/ Per thor Straten / Jan Andreasen
ImmunterapiKreft

A New Treatment Breakthrough for EGFR-mutated Lung Cancer

/ Seppo W. Langer
LungekreftNSCLC

Jens Benn’s Encounter with Heine Was Pivotal in His Choice of Lung Oncology

/ Jens Benn Sørensen / Amanda Feldballe Bernholm
Lungekreft

Norwegian and Nordic Lung Cancer Insights – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
Lung cancer-highlightsLungekreft
Hent flere
Back to top